Trials / Completed
CompletedNCT04930640
The Efficacy and Safety of SGF200 on Immune Enhancement
A 8 Weeks, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of SGF200 on Immune Enhancement
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Chonbuk National University Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
This study was conducted to investigate the efficacy and safety of SGF200 on immune enhancement.
Detailed description
This study was a 8 weeks, randomized, double-blind, placebo-controlled human trial. 100 subjects were randomly divided into SGF200 group or placebo group. The investigators measured Natural Killer cell activity, Cytokines(IL-2, IL-12, IFN-γ, TNF-α), questionnaire scores of upper airway infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | SGF200 group | 1 times a day, 1 capsule for 1 time, before breakfast meal, for 8 week |
| DIETARY_SUPPLEMENT | Placebo | Placebo for 8 week |
Timeline
- Start date
- 2021-01-25
- Primary completion
- 2021-04-06
- Completion
- 2021-05-26
- First posted
- 2021-06-18
- Last updated
- 2021-06-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04930640. Inclusion in this directory is not an endorsement.